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Abstract
The benefits of inhibiting vascular endothelial growth factor (VEGF) signaling in cancer patients are predominantly
attributed to effects on tumor endothelial cells. Targeting non–endothelial stromal cells to further impact tumor cell
growth and survival is being pursued through the inhibition of additional growth factor pathways important for the
survival and/or proliferation of these cells. However, recent data suggest that VEGF receptor (VEGFR)–specific in-
hibitors may target lymphatic vessels and pericytes in addition to blood vessels. Here, in fact, we demonstrate that
DC101 (40 mg/kg, thrice a week), an antibody specific to murine VEGFR2, significantly reduces all three of these
stromal components in subcutaneous (SKRC-29) and orthotopic (786-O-LP) models of renal cell carcinoma (RCC)
established in nu/nu athymic mice. Sunitinib (40 mg/kg, once daily), a receptor tyrosine kinase inhibitor of VEGFR2
and other growth factor receptors, also caused significant loss of tumor blood vessels in RCC models but had
weaker effects than DC101 on pericytes and lymphatic vessels. In combination, sunitinib did not significantly
add to the effects of DC101 on tumor blood vessels, lymphatic vessels, or pericytes. Nevertheless, sunitinib in-
creased the effect of DC101 on tumor burden in the SKRC-29 model, perhaps related to its broader specificity. Our
data have important implications for combination therapy design, supporting the conclusion that targeting VEGFR2
alone in RCC has the potential to have pleiotropic effects on tumor stroma.
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Introduction
The vascular endothelial growth factor family consists of placental growth
factor (PIGF), VEGF-A, VEGF-B, VEGF-C, and VEGF-D. These five
ligands have overlapping yet distinct capacities to activate three VEGF
receptors (VEGFR1, VEGFR2, and VEGFR3) [1,2]. In tumors,
VEGF-C– and VEGF-D–mediated activation of VEGFR3 can initiate
and maintain a network of lymphatic vessels [3], whereas it is mainly
the VEGF-A (VEGF)–mediated activation of VEGFR2 that supports
the development and maintenance of a tortuous, highly permeable blood
vessel network [4]. Although clinical targeting of lymphatic vessels in
cancer patients is at an early stage of development, the inhibition of
VEGF-VEGFR2–mediated signaling has received extensive effort
during recent decades after the discovery of VEGF [5].
The importance of VEGF-VEGFR2 signaling in cancer is most
clearly highlighted by the therapeutic benefits of bevacizumab, a hu-
manized antibody to VEGF, in colorectal [6,7], lung [8], renal [9],
and breast [10] cancer patients. Interestingly, to date, approvals by
regulatory agencies currently limit the use of bevacizumab to combi-
nation therapy, in part related to the minimal ability of bevacizumab
monotherapy to regress tumors despite significant inhibition of
measurable disease progression [11,12]. The benefits of combining
bevacizumab with cytotoxic therapy in patients are associated with an
increase in the maturational state of tumor blood vessels when VEGF-
VEGFR2 signaling is inhibited [13]. In effect, VEGF-VEGFR2–
targeted agents are thought to prune immature or nascent vessels that
lack a pericyte coating and enrich for pericyte-coated mature vessels
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[13–15]. Mature vessels are less leaky and would therefore contribute
less toward the typically high interstitial pressure in tumors that limits
the delivery of cytotoxic drugs to tumor cells [15–17].
The minimal ability of bevacizumab monotherapy to regress tu-
mors by denying them a blood vessel network may be related to
the inability of VEGF-VEGFR2–targeted agents to eliminate all tu-
mor blood vessels [15–20]. This idea has led to combination efforts
distinct from those using cytotoxic agents. VEGF-VEGFR2–targeted
agents are being combined with therapies targeting additional signal-
ing pathways that may directly or indirectly support endothelial cell
survival in the face of VEGF-VEGFR2 blockade [21]. Alternatively,
multitargeted small molecule receptor tyrosine kinase inhibitors
(TKIs) that inhibit the activation of VEGFR2 and additional growth
factor receptors are being used [14,17,19,22,23].
Pericytes surrounding mature tumor blood vessels reduce perme-
ability [24] and provide mechanical support [25]. Pericytes also pro-
vide soluble factors [26] to endothelial cells possibly allowing for the
survival of tumor endothelial cells during VEGF-VEGFR2 blockade.
These supportive cells are generally not thought to express VEGFR2
[27,28], so other growth factor pathways, in particular platelet-
derived growth factor (PDGF) receptor β (PDGFRβ), have been
targeted in combination approaches aiming to eliminate pericytes
to increase the susceptibility of endothelial cells forming mature
blood vessels to VEGF-VEGFR2 inhibition [14,22,23]. For exam-
ple, in subcutaneous xenograft models of pancreatic and non–small
cell lung cancer, targeting PDGFRβ-positive pericytes increased the
antivascular and antitumor effects of a rat antibody targeting murine
VEGFR2, DC101 [21].
In contrast to bevacizumab, the small molecule TKI sunitinib that
targets VEGFR1, VEGFR2, and VEGFR3, as well as PDGFRα and
PDGFRβ, Kit, Flt-3, and CSF-1R [27], is approved as a single agent
for the first-line treatment of metastatic renal cell carcinoma (RCC)
with a clear cell histologic component [29]. Approximately 80% of
sporadic RCC cases are of the clear cell or mixed clear cell type, with
57% of these patients having mutations in the von Hippel–Lindau
(vHL) gene, and 98% of these patients exhibiting loss of heterozy-
gosity [30–32]. Loss of vHL activity leads to constitutive activation of
the hypoxia-inducible factor 1 (HIF-1), resulting in increased produc-
tion of proangiogenic factors including VEGF [33]. Sunitinib not only
inhibits tumor growth in systemic therapy–naive metastatic RCC
patients with a clear cell histologic component but also significantly
increases tumor regressions when compared with the cytokine therapy
interferon α (31% vs 6% of patients) [34]. In a similar population of
RCC patients, bevacizumab monotherapy was associated with tumor
regression in only 13% of patients [35].
Mechanistically, it has been suggested that the ability to inhibit
both VEGFR2 and PDGFRβ signaling may enhance the efficacy
of sunitinib through increased antivascular effects compared with in-
hibitors specific for VEGF-VEGFR2, due to the targeting of peri-
cytes [27,36]. However, VEGF and PlGF targeting with a soluble
receptor construct (VEGF Trap) causes the loss of both normal tra-
cheal capillaries and associated pericytes, with the pericytes thought
to migrate away from the site of endothelial cell loss [37]. Further-
more, in a murine lung cancer model, VEGFR inhibition with
soluble VEGFR2 delivered by adenovirus not only reduced tumor
endothelial cells but also significantly reduced pericyte density
[38]. Pericyte targeting in this model with a VEGF-targeted agent
was thought to relate to reduced PDGFRβ activity downstream to
the loss of endothelial cell–derived PDGF ligand. However, the
demonstration of relatively low but detectable VEGFR2 expression
by bovine retinal pericytes suggests the potential for a more direct
effect [39].
The additional benefits of sunitinib in RCC patients compared with
those achieved to date with bevacizumab monotherapy may therefore
not be due to the targeting of PDGFRβ on pericytes but to the target-
ing of numerous pathways on endothelial, stromal and even tumor
cells by this multitargeted TKI. The targeting of pericytes, as well
as endothelial cells, may in fact only require the inhibition of VEGF
signaling. However, the ability of VEGF-VEGFR2–targeted agents to
reduce tumor pericytes in animal models has recently been shown to
be model dependent [40], so this possibility needs to be examined
specifically in RCC models.
In a separate area of tumor biology, VEGFR3 signaling is frequently
associated with the induction of a lymphatic network in tumors that
may contribute toward the metastasis of tumor cells to lymph nodes
and distant organs [3,41]. Inhibiting both VEGFR2 and VEGFR3
may target both tumor lymphatic vessels and blood vessels and, in
this way, increase the antitumor and antimetastatic effects of therapy
[41]. However, in line with the potential for more pleiotropic stromal
effects of agents targeting the VEGFR2 pathway alone than generally
considered, targeting of this pathway has the potential to exert potent
antilymphatic effects [42]. In particular, VEGFR2 activation sup-
ports lymphangiogenesis into a collagen scaffold covering a circum-
ferential area of mouse tail from which a band of dermal tissue was
removed [42]. In addition, VEGFR2 blockade with DC101 prevents
lymphatic vessel formation in regenerated mouse back skin after
punch biopsy [43]. These findings indicate that targeting VEGFR2
alone has the potential to inhibit tumor lymphangiogenesis and its
associated lymphatic metastasis.
From these discussions, it is clear that stromal cell effects of
VEGFR2 inhibition in RCC tumors may not be limited to endothelial
cells. In this regard, we have evaluated the effects of specifically tar-
geting VEGFR2 with DC101 on tumor blood vessels, pericytes,
and lymphatic vessels in two vHL-deficient RCC models. In addition,
we have compared the effects of DC101 with those of the multi-
targeted TKI sunitinib, alone or in combination.
Materials and Methods
Cell Lines
Caki-1 and ACHN cells were both obtained from American Type
Culture Collection (ATCC, Manassas, VA). The human clear cell
RCC cell line 786-O was obtained from ATCC, and 786-O cells ex-
pressing firefly luciferase (786-O-LP) were generated by retroviral
transfection, as previously described [44]. SKRC-29 RCC cells were
obtained from Cornell Medical Center (New York, NY) [45]. Cells
were cultured at 37°C/5% CO2 in RPMI 1640 + 0.8 mg/ml geneticin
(786-O and 786-O-LP), minimum essential medium (SKRC-29 and
ACHN), or McCoy’s 5A (Caki-1; Invitrogen Corporation, Carlsbad,
CA), supplemented with 10% fetal bovine serum (HyClone, Lenexa,
KY) and 1% GlutaMAX (Invitrogen Corporation). Cells were pas-
saged or collected for injection into mice using Trypsin EDTA
(Invitrogen Corporation).
vHL Gene Sequencing
Genomic DNA was extracted from cultured cells using the Qiagen
QiaAmp DNA mini kit (Valencia, CA). Exons 1, 2, and 3 of vHL were
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amplified from genomic DNA using Platinum HiFi PCR Supermix
(Invitrogen Corporation) and the following primer sets:
Exon 1, 5′-TGGGTCGGGCCTAAGCGCCGGGCCCGT-3′,
5′-AGTGGAAATACAGTAACGAGTTGGCCT-3′
Exon 2, 5′-CTTTAACAACCTTTGCTTGTCCCGATA-3′,
5′-GTCTATCCTGTACTTACCACAACACCT-3′
Exon 3, 5′-CTGAGACCCTAGTCTGCCACTGAGGAT-3′,
5′-CAAAAGCTGAGATGAAACAGTGTAAGT-3′
Reactions were carried out using a Px2 Thermal Cycler (Thermo
Scientific,Waltham,MA). Polymerase chain reactions were purified from
a 1.2% Agarose TAE gel using a Qiagen Qiaquick Gel Extraction Kit.
Purified products were then sequenced using the amplification primers
above or an additional set of primers in the case of the vHL exon 1:
5′GCGGCGTCCGGCCCGGGTGGTCTGGAT-3′ and
5′-GACTGCGATTGCAGAAGATGACCTGGG-3′.
Sequencing was performed on an ABI Prism 3700 DNA Analyzer
(Applied Biosystems, Foster City, CA) and analyzed using Vector
NTI Advance 10 software (Invitrogen Corporation).
Western Blot
Cells were grown to 80% confluence in complete medium, and
then culture supernatants were collected and cells were lysed with
radioimmunoprecipitation assay buffer (Santa Cruz Biotechnology,
Santa Cruz, CA). The protein concentration in cell lysates was mea-
sured using bicinchoninic acid (Pierce, Rockford, IL). Lysates (40 μg
protein/lane) were run on a 4% to 12% NuPAGE gel (Invitrogen
Corporation), transferred to nitrocellulose, and stained with primary
antibodies for vHL (Cell Signaling Technology, Inc, Denver, MA)
and β-actin (Sigma-Aldrich, St Louis, MO). Enhanced chemilumi-
nescence (Amersham, Piscataway, NJ) was used to develop images
on an LAS-4000 luminescent image analyzer (Fujifilm Life Sciences,
Stamford, CT).
Mice
Female nu/nu athymic mice (6-8 weeks old at study initiation;
Charles River Laboratories, Wilmington, MA) were used in accordance
with current regulations and standards of the US Department of Agri-
culture and the National Institutes of Health, with all animal research
methods approved by an internal animal care and use committee.
Orthotopic 786-O-LP Tumor Model
A longitudinal incision was made approximately 10 to 12 mm lat-
eral to the spine on the dorsal surface, directly above the kidney, in
isoflurane-anesthetized mice. The left kidney was isolated under the
abdominal muscle layer and grasped with blunt tipped forceps. The
kidney was moved to the site of incision, and 3 × 106 786-O-LP cells
were injected just below the renal capsule in 100% Matrigel (BD
Biosciences, San Jose, CA), in a 50-μl volume using a 30-gauge needle.
The kidney was returned to the peritoneal cavity, and the surgical site
was closed first by suturing the abdominal wall with 4-0 silk sutures
and then by closing the skin with wound clips. Tumor burden was
evaluated in live animals by measuring bioluminescence intensity
(BLI) using the IVIS 200 in vivo imaging system, as per the manu-
facturer’s instructions (Xenogen/Caliper Life Sciences, Hopkinton,
MA). BLI was evaluated 12 minutes after intraperitoneal injection
of 150 mg/kg D-luciferin (Xenogen), as previously described [44].
Ten days after tumor cell injection, mice were randomized by BLI
into treatment groups, and BLI was evaluated during the treatment
period. Furthermore, at the end of dosing in studies evaluating the
antitumor effects of treatment, tumor burden was evaluated by
measuring the weight of the injected kidney. Effects of treatment on
bioluminescence signal (log10[BLI]) over time were evaluated by
repeated-measures analysis of variance (ANOVA; n = 10-11 mice
per group; JMP version 5; SAS, Cary, NC). The effects of treatment
on tumor-bearing kidney weight were evaluated by one-way ANOVA
followed by Fisher least significant difference (LSD; n = 10-11 mice
per group; SigmaStat, Point Richmond, CA).
SKRC-29 Subcutaneous Xenograft Tumor Model
Mice were injected subcutaneously into the right flank with 2 ×
106 SKRC-29 cells, in 50% culture medium/50% Matrigel. Tumor
volumes were calculated as π/2(L × W 2), where L is the longest diam-
eter measured with calipers and W is the diameter perpendicular to L.
When the mean tumor volume reached approximately 250 mm3, mice
were randomized by tumor volume into treatment groups and tumor
volume was recorded twice weekly thereafter. The effects of treatment
on tumor growth were evaluated by repeated-measures ANOVA (n =
11-12 mice per group).
Treatments
DC101 (ImClone Systems, Branchburg, NJ) was diluted in USP
saline (Braun Medical, Inc, Irvine, CA) and dosed Monday-Wednesday-
Friday at 40-mg/kg body weight. Sunitinib (Sequoia Research Products,
Pangbourne, UK) was prepared in 0.5% methyl cellulose (Sigma-
Aldrich) with 0.2% Tween 80 (Sigma-Aldrich), and dosed by oral
gavage at 40 mg/kg, once a day. All treatments were started on the
same day. When dosed in combination, on days in which both drugs
were administered, sunitinib was administered approximately 1 hour
before DC101.
Thin-Section Immunohistochemical Analysis
SKRC-29 tumors were removed 7 days after the start of treatment,
fixed in 10% neutral-buffered formalin at 4°C for 24 hours, and then
embedded in paraffin. Five μm sections were double-stained with
monoclonal antibodies for CD31 (Gene Tex, Irvine, CA) and alpha-
smooth muscle actin (αSMA; Epitomics, Burlingame, CA), using Alexa
Fluor 488 (Molecular Probes, Eugene, OR) and tetramethyl rhodamine
iso-thiocyanate (BioFX, Owings Mills, MD) to fluorescently detect the
proteins, respectively. In addition, thin sections of saline-treated SKRC-
29 tumors, as well as 786-O-LP tumors, were stained for CD31/αSMA/
VEGFR2 and CD31/LYVE-1/VEGFR2 using the antibodies described
above and a monoclonal antibody to VEGFR2 (Abcam, Cambridge,
MA) and/or a rabbit polyclonal antibody to LYVE-1 (Novus Biologicals,
Littleton, CO). CD31, αSMA, and LYVE-1 were visualized with Alexa
Flour 488 or TRITC in these sections, and VEGFR2 was visualized
with Alexa Fluor 647 (Molecular Probes).
Fluorescent images of thin sections at 400× magnification were
captured using EZ-C1 software with a Nikon C1 confocal micro-
scope (Nikon Instruments, Inc, Melville, NY). Quantitative analyses
of CD31/αSMA–stained sections were performed on images from
five fields of view from the tumor periphery (within 0.44 mm2 from
the tumor edge) and five from the tumor core (>0.5 mm2 from the
tumor edge). After finding no effect of tumor location (not shown),
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these measurements were pooled for a total of 10 fields of view per
tumor. NIS Elements software (Nikon Instruments, Inc) was used
for the quantification of total positive signal area in the captured
fields of view, expressed as a percentage of total field of view area.
Treatment effects on histologic measurements were evaluated by
one-way ANOVA, followed by Fisher LSD (n = 6 tumors per group).
Thick-Section Histologic Analysis
SKRC-29 tumors and 786-O-LP tumor-bearing kidneys were re-
moved 7 days after the start of treatment and placed in 4% parafor-
maldehyde (EM Sciences, Hatfield, PA) for 1 hour. Tissues were then
placed in 1% paraformaldehyde on ice until 200-μm sections were
cut with a vibrating blade microtome (VT1000S; Leica, Bannockburn,
IL) and placed in Lab-Tek chamber slides (Nunc, Rochester, NY).
Sections were stained with primary antibodies for CD31 (Gene
Tex), αSMA (Epitomics), type IV collagen (Millipore, Billerica,
MA), NG2 (Millipore), LYVE-1 (Novus Biologicals), and/or mouse
pan-endothelial cell antigen (Meca-32; BD Pharmingen, Franklin
Lakes, NJ). For fluorescent detection, an Alexa Fluor 488–conjugated
secondary antibody was used for CD-31 (Molecular Probes), and a
TRITC-conjugated antibody was used for αSMA and LYVE-1
(BioFX). Meca-32 and NG2 were visualized using Alexa Fluor 647,
and type IV collagen was visualized with Alexa Fluor 633 (Molecular
Probes). CD31 staining was used for evaluating treatment effects on
blood vessels throughout, given that nearly all CD31-positive vessels
were also Meca-32–positive (not shown).
For the analysis of treatment effects on SKRC-29 tumors, the fol-
lowing triple stains were performed: CD31/αSMA/type IV collagen,
CD31/αSMA/NG2, and CD31/LYVE-1/type IV collagen (n = 3 tu-
mors per treatment group). In 786-O-LP tumors, the following triple
stains were performed: CD31/αSMA/type IV collagen and CD31/
LYVE-1/Meca-32 (n = 6 tumors per group). Images were acquired
using EZ-C1 software on a Nikon C1 confocal microscope. A total
of 10 Z-stacks were captured per stained tissue section. Selection of
the fields of view for analysis involved randomly selecting hot spots
for αSMA staining in the SKRC-29 model. Hot spots of αSMA
staining were again part of the selection criteria in the 786-O-LP
model, but selected areas were also required to be in the tumor
cell–rich regions and distinct from normal regions of the adjacent
kidney dominated by tubular structures and/or glomeruli.
For the evaluation of SKRC-29 tumors, because the effect of treat-
ment on type IV collagen and NG2-positive structures staining was
minimal (not shown), the analysis of CD31 and αSMA staining
from the CD31/αSMA/type IV collagen and CD31/αSMA/NG2
triple-stained sections was pooled, making for a total of 20 Z-stacks
analyzed per tumor. The quantification of effects of treatment on tu-
mor stroma included the counting of all individual vessel like struc-
tures in one plane in the middle of each captured Z-stack using
AutoQuant software (Media Cybernetics, Inc, Acton, MA) and the
characterization of these structures as a single or a double positive for
CD31 and αSMA (n = 3 tumors per group). The same analysis was
performed to evaluate LYVE-1–positive vessel-like structures in the
SKRC-29 model. In addition to the vessel counting method, the total
volume of CD31- and αSMA-stained pixels throughout all CD31/
αSMA/type IV collagen– and CD31/αSMA/NG2–stained Z-stacks
was measured with NIS Elements software. The results using this last
method were very similar to those obtained using the manual counting
method described above, so only the NIS Elements method was used
in the 786-O-LP–stained tumors for CD31, αSMA, and LYVE-1
analyses (n = 6 tumors per group). The effects of treatment on quanti-
tative measures of immunostaining were evaluated by one-way ANOVA
followed by Fisher LSD, with n always taken as the number of tumors
per treatment group.
Results
SKRC-29 Subcutaneous Tumor Model
The SKRC-29 cells used in these studies have an early stop codon
in the vHL gene because of a C203A base pair mutation, causing a
lack of vHL protein expression compared with vHL wild type RCC
cells (Figure 1). Thus, SKRC-29 cells exhibit a major characteristic of
clear cell RCC [17,30,32], although, at the time of isolation of this
cell line from a patient, the characterization of the histology of the
tumor was not reported [45]. SKRC-29 cells formed rapidly growing
tumors when implanted subcutaneously into athymic nu/nu mice
(Figure 2A).
An antibody to mouse VEGFR2, DC101, and a TKI of VEGFR2,
sunitinib, had similar and potent antitumor effects in the SKRC-29
subcutaneous xenograft RCC model (P < .001; Figure 2A). Inter-
estingly, although both agents target VEGFR2, the combination of
sunitinib and DC101 resulted in a greater inhibition of tumor growth
than either monotherapy (P < .02). Furthermore, tumors in 6 of
11 mice in the DC101 + sunitinib group decreased in volume during
26 days of therapy compared with 1 of 12 and 1 of 11 in the DC101
and sunitinib monotherapy groups, respectively (P = .002 for an effect
of treatment by χ 2 test).
To examine the mechanisms underlying the efficacy illustrated in
Figure 2A, SKRC-29 tumors were harvested after 7 days of therapy
for the analysis of the density of CD31-positive blood vessels, LYVE-
1–positive lymphatic vessels [42] and α-smooth muscle actin (αSMA)–
positive pericytes [14,17,21,46]. This time point was selected because
tumors in all treatment groups were still of similar size, and signifi-
cant blood vessel loss occurs in animal models by 7 days of VEGFR2-
targeted therapy [17,20].
In thick sections (200 μM) of tumors stained for both CD31 and
αSMA, it was rare to find CD31-positive vessel-like structures con-
sisting of one or more continuous linear segments not associated with
αSMA-positive pericytes (Figure 3, A and B). In contrast, numerous
vessel-like structures positive for αSMA only, or CD31-positive en-
dothelial cells in association with αSMA-positive structures were ob-
served. Sunitinib significantly reduced the density of αSMA/CD31
double-stained vessels (P < .05), frequently referred to as mature
or established vessels [14,21]. In contrast, sunitinib increased the
Figure 1. vHL mutant RCC lines lack vHL protein expression. Forty
micrograms of total lysate protein per lane from the indicated cell
lines was run on a 4% to 12% NuPAGE gel. After transfer to nitro-
cellulose, blots were stained for vHL and β-actin (loading control).
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frequency of vessel-like structures staining positively for αSMA only
(P < .05) but did not affect the total number of αSMA structures.
This suggests sunitinib depletes CD31-positive endothelial cells,
without affecting the pericytes that were supporting these lost vessels,
as previously reported [17]. This is in contrast to DC101, which de-
pleted both total CD31-positive and total αSMA-positive vessel-like
structures (P < .05), but did not affect the density of αSMA-only
structures (Figure 3, A and B). DC101 therefore seems to be targeting
both CD31-expressing blood vessels as well as the pericytes that sup-
port these vessels. In combination, the histologic effects of DC101 +
sunitinib were not significantly different from those of DC101 alone
(Figure 3, A and B).
It was somewhat unexpected that a more specific VEGFR2-targeting
agent (DC101) reduced pericytes to a greater extent than a potent
VEGFR2-targeted agent that also targets PDGFRβ [21,27]. Additional
quantitative methods were therefore performed to confirm the results
presented in Figure 3, A and B. First, total CD31- and total αSMA-
positive volumes were summed separately through the entire captured
image stacks from thick sections, with a computerized process that is
much less time-consuming than counting individual vessels (Figure 3C ).
Results of this volume quantification were very similar to those obtained
by counting and characterizing individual structures in tumor sections,
with both DC101 and sunitinib, alone or in combination, reducing
CD31 staining volume (P < .05), but only DC101 significantly reducing
αSMA staining volume (Figure 3C). The effects of DC101 + sunitinib
combination therapy on CD31 and αSMA staining volume were not
significantly different from those of DC101 alone.
As an additional quantitative method, we evaluated the effects
of treatment in thin sections of formalin-fixed paraffin-embedded tu-
mors using methods more frequently used in evaluating the effects of
antivascular agents in xenograft models [17,20,21]. As with thick-
section analyses, sunitinib and DC101, alone or in combination,
had similar potency in reducing the area of CD31-expressing tumor
blood vessels (P < .05; Figure 3D). Moreover, DC101 had a dramatic
effect on the total αSMA-positive area (P < .05), whereas the trend
for an effect of sunitinib did not reach statistical significance (Fig-
ure 3D). It is noteworthy that the density of αSMA staining relative
to CD31 was much lower in thin sections of formalin-fixed paraffin-
embedded tissue compared with thick sections that undergo rela-
tively minimal fixation and tissue processing before staining (Figure 3,
C and D). This difference may indicate improved αSMA staining
sensitivity or better preservation of αSMA-positive structures with
the thick-section methods used.
786-O-LP Orthotopic Tumor Model
To examine the generality of the findings in the SKRC-29 subcu-
taneous xenograft tumor model, we used a luciferase-expressing clear
cell RCC line, 786-O-LP (for parental line, see Gnarra et al. [30]).
The vHL gene in this line also possesses genetic changes (G311 de-
letion) associated with a lack of vHL protein expression (Figure 1).
786-O-LP tumor cells were surgically implanted just under the renal
capsule of mice. DC101 and DC101 + sunitinib both tended to re-
duce the BLI emitted from the tumor growing within live mice up to
the point of study termination, but the effect did not reach statistical
significance (Figure 2B). As a measure of total tumor burden, we also
recorded the weight of the tumor-bearing kidneys at the end of the
study (Figure 2C ). The weight of the non–tumor-bearing kidney
from the control group mice was also recorded as a measure of normal
kidney weight. DC101 and DC101 + sunitinib both significantly
Figure 2. Targeting VEGFR2 significantly inhibits xenograft tumor
growth in RCC models. (A) DC101 (40 mg/kg, intraperitoneally,
Monday-Wednesday-Friday) and sunitinib (40 mg/kg, per os, once
daily), alone or in combination, significantly decreased the growth
of established subcutaneous SKRC-29 tumors in nu/nu athymic
mice. (B) Treatments, as described in panel A, did not significantly
impact the change in bioluminescence signal over time, emitted
from 786-O-LP cells growing in the kidney. Inset illustrates bio-
luminescence image on IVIS 200, with red indicating regions of
greatest signal and purple indicating regions of lowest detect-
able signal. (C) DC101 alone or in combination with sunitinib,
but not sunitinib alone, significantly decreased the weight of
786-O-LP tumor-bearing kidneys harvested after 32 days of treat-
ment. **P < .01 versus control = saline treatment. All graphs plot
mean ± SEM.
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reduced the weight of the tumor-bearing kidney (P < .004) with
similar potency (P = .37), but the effects of sunitinib monotherapy
did not reach statistical significance versus control (P = .14). Of note
for the kidney contralateral to the kidney injected with tumor cells,
no tumor cells were observed by whole body bioluminescence im-
aging and no abnormalities were visualized at sacrifice in any treat-
ment group.
To study the mechanisms underlying the treatment effects il-
lustrated in Figure 2, B and C , 786-O-LP tumors were harvested
after 7 days of therapy for the analysis of the volume of CD31- and
αSMA-positive staining, in thick sections only. Both DC101 and
sunitinib significantly reduced CD31 staining, with DC101 having
a greater effect (P < .05; Figure 4, A and B). Similarly, DC101 reduced
the volume of αSMA staining by 60% (P < .05), whereas sunitinib
reduced this pericyte-associated staining by only 23% (P < .05). For
both CD31 and αSMA, the effects of combination therapy with
DC101 + sunitinib were not significantly different from those of
DC101 alone.
Treatment Effects on Tumor Lymphatic Vessels
LYVE-1 staining density was evaluated in tumor sections to exam-
ine the effects of targeting VEGFR2 on lymphatic vessels [42]. In thick
sections of SKRC-29 subcutaneous tumors, DC101 significantly re-
duced lymphatic vessel density (P < .05), whereas sunitinib did not
(Figure 5, A and B). The combination DC101 + sunitinib had an ef-
fect similar to that of DC101 alone. In volumetric quantification of
LYVE-1 staining in thick sections of 786-O-LP orthotopic tumors,
Figure 3. DC101 targets blood vessels and pericytes in subcutaneous SKRC-29 RCC tumors. (A) Two hundred-micrometer-thick sections
of SKRC-29 subcutaneous xenograft tumors grown in nu/nu athymic mice were immunostained for CD31 and αSMA. Tumors were
harvested after 7 days of treatment with DC101 (40 mg/kg, intraperitoneally, Monday-Wednesday-Friday) and sunitinib (40 mg/kg,
per os, once daily), alone or in combination. All treatments significantly reduced CD31-positive vessels, but only DC101 and DC101 +
sunitinib reduced total αSMA staining. (B) Representative images for the analysis reported in panel A, with red = αSMA and green =
CD31-positive fluorescence. Bars, 20 μm. (C) Volume of positive staining calculated with NIS Elements software is reported for the
same three-dimensional image stacks used for the counting of individual structures in panel A, with similar effects of treatment. (D)
Five-micrometer-thin sections of formalin-fixed paraffin-embedded tumors, harvested after 7 days of treatment with DC101 and sunitinib,
alone or in combination, were stained for CD31 and αSMA. As above, all treatments significantly reduced CD31-positive vessels, but
only DC101 and DC101 + sunitinib reduced total αSMA staining. All graphs plot mean ± SEM. *P < .05 versus control = saline treatment;
**P < .01 versus control.
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both DC101 and sunitinib reduced lymphatic vessel density, with
DC101 having a greater effect than sunitinib (P < .05) and the com-
bination therapy having an effect similar to that of DC101 alone
(Figure 5, C and D).
Colocalization of VEGFR2 with CD31, LYVE-1, and αSMA
Whereas the effects of a VEGFR2-specific agent such as DC101
on lymphatic endothelial cells and pericytes may be indirect and po-
tentially downstream to the effects on endothelial cells, a more direct
effect is possible [39,43]. A direct effect would require VEGFR2
expression by lymphatic endothelial cells and pericytes, so we evalu-
ated the colocalization of VEGFR2 immunoreactivity with LYVE-1–
positive lymphatic vessels and αSMA-positive pericytes in sections
of tumors from control mice. As expected, CD31-positive endothe-
lial cells were VEGFR2-immunoreactive in the SKRC-29 and 786-
O-LP models (Figure 6, A and B). VEGFR2 immunoreactivity also
colocalized with αSMA-positive (Figure 6, C and D) and LYVE-1–
positive (Figure 6, E and F ) structures, supporting VEGFR2 expres-
sion by pericytes and lymphatic endothelial cells in these models.
Discussion
The genetic diversity of cancer cells and the biologic complexity of
tumor growth underlie a significant current effort to develop com-
bination therapies targeting multiple pathways. We recently demon-
strated that two characteristics associated with the best combination
of targeted agents were inhibition of resistance mechanisms of one
agent in the combination by another agent and a nonoverlapping
spectrum of activity [47]. This last factor was related to the finding
that targeting one pathway obviated the need to target a separate path-
way in the models tested, despite the fact that both agents had anti-
tumor effects on their own. Here, we demonstrate another of these
instances, where an agent specifically targeting VEGFR2 was found
to have effects on the tumor stroma frequently thought to be achiev-
able only by adding agents targeting different pathways in a combina-
tion approach. More specifically, an antibody targeting VEGFR2 not
only dramatically reduced tumor blood vessel density in vHL-deficient
RCC models as expected but also reduced the density of tumor peri-
cytes and lymphatic vessels.
The importance of VEGF-VEGFR2 signaling in endothelial cell
functioning within tumors is well established. Early in the first week
of treatment with VEGF-VEGFR2–specific agents in preclinical
cancer models, the large-diameter, highly permeable, and tortuous tu-
mor blood vessel networks are normalized, in that blood vessels lose
more than 85% of their endothelial cell fenestrations after only 1 day
of treatment [19], and vessel diameter is decreased within 2 days [18].
Related to increased vessel permeability, the typically high interstitial
fluid pressure within the tumor [48] is significantly reduced within
3 days of DC101 treatment [46]. This effect likely underlies the re-
ported increase in the delivery of blood-borne compounds to tumors
during VEGF-VEGFR2–targeted therapy [15,17,46]. Furthermore,
this window of increased drug access may contribute toward the dem-
onstrated therapeutic benefits of an antibody to VEGF, bevacizumab,
in combination with cytotoxic therapy in patients [6–8,10,15].
After 1 week of VEGF-VEGFR2–targeted therapy, following this
period of more normal vessel functioning, tumor blood vessels as well
as some blood vessels in normal tissue are lost [18–20,49]. But in all
cases, a small population of tumor blood vessels survive, likely contrib-
uting to the finding that tumors do not significantly regress with
VEGF-VEGFR2–specific agents [20,49,50]. The remaining vessels
are often considered to be the more mature pretreatment vessels that
survived specific VEGF-VEGFR2–targeted therapy through a supply
of additional trophic support from pericytes [14,21,46]. Targeting of
the remaining vessels has therefore emerged as a potential combination
approach, supported by the finding that targeting PDGFRβ, a recep-
tor important for the survival and functioning of pericytes, in addi-
tion to targeting VEGF-VEGFR2 signaling, can increase vessel loss
and antitumor effects in models of pancreatic islet cell cancer [14],
pancreatic cancer, and non–small cell lung cancer [21].
Figure 4. DC101 targets blood vessels and pericytes in orthotopic
786-O-LP RCC tumors. (A) Two hundred-micrometer-thick sections
of 786-O-LP tumor-bearing kidneys were immunostained for CD31
and αSMA. Tissues were harvested after 7 days of treatment with
DC101 (40 mg/kg, intraperitoneally, Monday-Wednesday-Friday)
and sunitinib (40 mg/kg, per os, once daily), alone or in combination.
All treatments significantly reduced the volume of CD31-positive
and αSMA-positive staining, with DC101-containing regimens hav-
ing the greatest effect. *P < .05 versus control = saline treatment;
**P < .01 versus control. Mean ± SEM is plotted. (B) Representa-
tive images for the analysis reported in panel A, with red = αSMA
and green = CD31-positive fluorescence. Bar, 20 μm.
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Yet here we show in tumor models with an impaired ability to
downregulate HIF-1 activity, a commonly observed deficiency in
clear cell RCC, that targeting VEGFR2 alone with a specific mono-
clonal antibody causes the loss of tumor blood vessels as well as their
associated αSMA-positive pericytes. Surprisingly, the magnitude of
the effect of an antibody specific to VEGFR2 on pericytes was greater
than that achieved with a small molecule TKI that potently inhibits
both VEGFR2 and PDGFRβ [27]. The dose of sunitinib used in the
current studies (40 mg/kg, PO, once daily) is the most frequently used
dose in the literature because of its maximal antitumor effect [23,27]
and significant antivascular effect [17]. However, this dose inhibited
VEGFR2 phosphorylation in tumors at 12 but not 24 hours after
treatment, whereas a higher dose (80 mg/kg) inhibited PDGFRβ
phosphorylation at both time points [27]. It is therefore possible that
a higher dose of sunitinib would achieve the same magnitude of ef-
fect as DC101 on tumor pericytes observed in the present studies.
Nevertheless, the modest effect of 40 mg/kg sunitinib in the 786-
O-LP model (23% decrease in αSMA-positive pericyte staining) is
consistent with a reported 33% decrease in αSMA-positive pericytes
in tumors treated with AG013736 [19], a TKI targeting VEGFRs,
PDGFRs, and cKit. Moreover, the absence of an effect on tumor
αSMA-positive pericytes in the presence of a significant antivascular
effect after 7 days of treatment with sunitinib in the SKRC-29 model
is very similar to results reported in a glioma model [17]. Regardless
Figure 5. DC101 targets lymphatic vessels in RCC tumors. (A) SKRC-29 subcutaneous tumors were harvested after 7 days of treatment
with DC101 (40 mg/kg, intraperitoneally, Monday-Wednesday-Friday) and sunitinib (40 mg/kg, per os, once daily), alone or in combina-
tion, and 200-μm-thick sections were stained for LYVE-1. Only DC101 and DC101 + sunitinib reduced total LYVE-1–positive lymphatic
vessel density. (B) Representative photomicrographs of LYVE-1–immunostained tumor sections with red = LYVE-1–positive fluores-
cence for panel A. (C) 786-O-LP orthotopic tumors were harvested after 7 days of treatment as above, and 200-μm-thick sections were
stained for LYVE-1. DC101 and sunitinib both reduced total LYVE-1–positive stained volume, calculated using NIS Elements software,
with DC101 having a greater magnitude effect. (D) Representative images of LYVE-1–immunostained tumor sections with red = LYVE-
1–positive fluorescence for panel C. All graphs plot mean ± SEM. Bars, 20 μm. *P < .05 versus control = saline treatment; **P < .01
versus control.
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of the effects of TKIs, however, results with DC101 clearly show that
targeting blood vessel–associated pericytes does not require the target-
ing of a receptor other than VEGFR2 in renal cell cancer models.
Combination approaches seeking to add to the benefits of VEGF-
VEGFR2 pathway–targeted agents may also include the targeting of
lymphatic endothelial cells by inhibiting pathways important for
lymphangiogenesis such as VEGFR3 [41]. This combination strategy
aims to limit the lymphatic spread of metastasis while also inhibiting
angiogenesis-dependent components of cancer progression. Yet, in
two RCC models, a significant depletion of tumor lymphatic vessels
was achieved by targeting VEGFR2 alone with DC101. This find-
ing is in agreement with the reported effects of targeting VEGFR2
on lymphangiogenesis after skin damage in animal models [42,43].
Although the effects of DC101 on tumor pericytes and lymphatic
endothelial cells may be indirect [37,38], the immunohistochemi-
cal colocalization of VEGFR2 and LYVE-1, as well as VEGFR2
and αSMA, supports the possibility that targeting may also be di-
rect [39,43].
The pleiotropic effects of VEGFR2-targeted therapy on tumor
stroma were consistent in models established with two different cell
lines in two different tissue environments; however, the impact of
these effects on tumor burden was weaker in the orthotopic 786-
O-LP model than in the subcutaneous SKRC-29 model. We have
not compared the antitumor effects of treatment in both environ-
ments in models established with the same cell line; however, the
effects of sunitinib at the 40-mg/kg dose level have recently been
evaluated in a subcutaneous tumor model established with the parental
line for 786-O-LP, 786-O [51]. Sunitinib caused tumor stasis in this
subcutaneous model, in contrast to the lack of effect reported here
when 786-O-LP cells were grown orthotopically. This suggests that
the differences in efficacy may be due to environmental factors, with
the kidney environment allowing for tumor growth despite significant
antivascular effects. Nevertheless, a definitive conclusion cannot be
made without using the same cell lines in the two model systems.
In summary, results indicate that targeting VEGFR2 with an anti-
body in vHL-deficient RCC may obviate the need for other agents
specifically targeting pericytes and lymphatic vessels to increase anti-
tumor effects. This conclusion is highlighted by the finding that
combining DC101 with a TKI that inhibits VEGFR2, VEGFR3,
and PDGFRβ did not significantly increase the loss of tumor blood
vessels, pericytes, or lymphatic vessels caused by DC101 alone. Never-
theless, adding sunitinib to DC101, an antibody that specifically tar-
gets murine VEGFR2 [52], reduced the tumor volume to a greater
extent than DC101 alone in one model (SKRC-29). This suggests that
the multiple kinases inhibited by sunitinib on tumor and nontumor
cells may still contribute toward tumor growth in ways separate from
stroma-related mechanisms and distinct from the mechanistic targets
of VEGFR2 antibody therapy. These distinct mechanisms will likely
be of most value in designing novel combination approaches.
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